Cargando…

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program

CONTEXT: Despite having normal growth hormone (GH) secretion, individuals with Turner syndrome (TS) have short stature. Treatment with recombinant human GH is recommended for TS girls with short stature. OBJECTIVE: This work aimed to evaluate the effectiveness and safety of Norditropin (somatropin,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Backeljauw, Philippe, Blair, Joanne C, Ferran, Jean-Marc, Kelepouris, Nicky, Miller, Bradley S, Pietropoli, Alberto, Polak, Michel, Sävendahl, Lars, Verlinde, Franciska, Rohrer, Tilman R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505549/ https://www.ncbi.nlm.nih.gov/pubmed/36947589 http://dx.doi.org/10.1210/clinem/dgad159

Ejemplares similares

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER
por: Sävendahl, Lars, et al.
Publicado: (2021)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
por: Biller, Beverly M K, et al.
Publicado: (2023)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS
por: Ross, Judith L, et al.
Publicado: (2022)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

CORRIGENDUM for “Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program”
Publicado: (2020)

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study
por: Polak, Michel, et al.
Publicado: (2017)

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study
por: Blankenstein, Oliver, et al.
Publicado: (2017)

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
por: Höybye, Charlotte, et al.
Publicado: (2013)

Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program
por: Lee, Peter A., et al.
Publicado: (2015)

SAT-282 Outcomes in Children Treated with Growth Hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS)
por: Angulo, Moris, et al.
Publicado: (2019)

Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis
por: Ross, Judith, et al.
Publicado: (2023)

Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence
por: Romano, Alicia, et al.
Publicado: (2021)

Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age
por: Juul, Anders, et al.
Publicado: (2022)

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
por: Höybye, Charlotte, et al.
Publicado: (2022)

GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome
por: Dahlgren, Jovanna, et al.
Publicado: (2021)

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use
por: Hokken-Koelega, Anita, et al.
Publicado: (2011)

A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome
por: Clayton, P, et al.
Publicado: (2013)

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome
por: Stevens, A, et al.
Publicado: (2014)

Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis
por: Sheanon, Nicole M., et al.
Publicado: (2015)

OR18-6 Tracking the Diagnosis and Progression of Madelung Deformity in Pediatric Turner Syndrome Patients
por: Backeljauw, Philippe F, et al.
Publicado: (2022)

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status
por: Jorge, Alexander A L, et al.
Publicado: (2022)

Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)
por: Vyberg, Mogens, et al.
Publicado: (2015)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

MON-249 Algorithm-Driven Electronic Health Record Notification Enhances the Detection of Turner Syndrome
por: Alexandrou, Eirene, et al.
Publicado: (2019)

A Case Report of Turner Syndrome with Graves’ Disease during Recombinant Human GH Therapy and Review of Literature
por: Nakagawa, Makio, et al.
Publicado: (2006)

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults
por: Allen, D B, et al.
Publicado: (2015)

Insights from circulating microRNAs in cardiovascular entities in turner syndrome patients
por: Abu-Halima, Masood, et al.
Publicado: (2020)

The crosstalk between FGF21 and GH leads to weakened GH receptor signaling and IGF1 expression and is associated with growth failure in very preterm infants
por: Mistry, Jayna N., et al.
Publicado: (2023)

Continuous measurement of aortic dimensions in Turner syndrome: a cardiovascular magnetic resonance study
por: Subramaniam, Dhananjay Radhakrishnan, et al.
Publicado: (2017)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

MicroRNA-126-3p/5p and Aortic Stiffness in Patients with Turner Syndrome
por: Abu-Halima, Masood, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8rt1ksrosnl5rdcfjqokiata36